Novartis Investigative Site

Gdansk, Poland 80-958

0 studies enrolling now · 1 studies all time

What they study most

Symptomatic Refractory Resistant Carcinoid Disease

Studies at this site

• Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease — Completed